Methods for chelation therapy
The invention relates to compositions and methods of treatment using an iron chelator, an antioxidant, estrogen, and/or combinations thereof, optionally, linked to a nanoparticle, to treat a subject in need thereof. The compositions and methods may be used to restore or protect the normal functions of osteoblast and osteoclast by depleting iron and inhibiting oxidative damage. The compositions and methods may also be used to increase the bone formation rate in a subject.
1. A method of treating a neurological disease where excess metal ions have a role in the disease pathogenesis, the method comprising: providing a chelator nanoparticle conjugate capable of crossing the blood brain barrier; administering the chelator nanoparticle to a subject; and chelating a metal in the subject, thereby treating the neurological disease in the subject, wherein the chelator comprises:
2-methyl-N-(3′-aminopropyl)-3-hydroxyl-4-pyridinone,
desferrioxamine covalently linked through amido bonds to a polystyrene microsphere comprising magnetite, or
1-N-docosyltriethylenetetraminepentaacetic acid.
2. The method according to claim 1 , wherein the neurological disease is selected from the group consisting of Alzheimer's Disease, Parkinson's disease, and Friedreich's ataxia.
3. The method according to claim 1 , wherein the disease comprises Alzheimer's Disease.
4. The method according to claim 1 , wherein the nanoparticle comprises a polystyrene microsphere.
5. The method according to claim 1 , further comprising reducing amyloid-β formation in the subject.
6. The method according to claim 1 , wherein crossing the blood brain barrier comprises utilizing a LDL transport mechanism.
7. The method according to claim 1 , wherein providing comprises conjugating a metal chelator to a nanoparticle to produce a chelator nanoparticle conjugate capable of crossing the blood brain barrier.
8. The method according to claim 1 , wherein the metal comprises Fe, Al, Cu, or Zn.
9. The method according to claim 1 , wherein the subject is a patient diagnosed with the neurological disease.
10. A method of treating a neurological disease where excess metal ions have a role in the disease pathogenesis, the method comprising: providing a chelator nanoparticle conjugate capable of crossing the blood brain barrier; administering the chelator nanoparticle to a subject; and chelating a metal in the subject, thereby treating the neurological disease in the subject, wherein the nanoparticle comprises a polystyrene microsphere.
11. The method according to claim 10 , wherein the chelator comprises 2-methyl-N-(3′-aminopropyl)-3-hydroxyl-4-pyridinone.
12. The method according to claim 10 , further comprising reducing amyloid-β formation in the subject.
13. The method according to claim 10 , wherein the chelator comprise desferrioxamine.
14. The method according to claim 13 , wherein the desferrioxamine is covalently linked through amido bonds to a polystyrene microsphere comprising magnetite.
15. The method according to claim 10 , wherein the chelator comprises 1-N-docosyltriethylenetetraminepentaacetic acid.
16. A method of treating a neurological disease selected from the group consisting of Alzheimer's Disease, Parkinson's disease, and Friedreich's ataxia, the method comprising: conjugating a metal chelator to a nanoparticle to produce a chelator nanoparticle conjugate capable of crossing the blood brain barrier; administering the chelator nanoparticle to a subject; and chelating a metal in the subject, thereby treating the neurological disease in the subject.
17. The method according to claim 16 , wherein the chelator comprises 2-methyl-N-(3′-aminopropyl)-3-hydroxyl-4-pyridinone.
18. The method according to claim 16 , wherein the chelator comprises desferrioxamine.
19. The method according to claim 18 , wherein the desferrioxamine is covalently linked through amido bonds to a polystyrene microsphere comprising magnetite.
20. The method according to claim 16 , wherein the chelator comprises 1-N-docosyltriethylenetetraminepentaacetic acid.